Abarelix vs Degarelix
Research Verdict
Degarelix is the stronger research reference for the stated comparison criteria. Degarelix: FDA approved 2008 (Firmagon) for advanced prostate cancer, Phase 3 (CS21, Van Poppel et al.
Quick Answers
Which is better, Abarelix or Degarelix?
Degarelix is the stronger research reference for the stated comparison criteria. Degarelix: FDA approved 2008 (Firmagon) for advanced prostate cancer, Phase 3 (CS21, Van Poppel et al.
What is the key difference between Abarelix and Degarelix?
Degarelix achieves rapid testosterone suppression without the anaphylaxis risk that ended abarelix - it is the direct clinical successor with a substantially better safety profile.
Evidence Comparison
Degarelix: FDA approved 2008 (Firmagon) for advanced prostate cancer, Phase 3 (CS21, Van Poppel et al. 2008, n=610) showing non-inferior testosterone suppression vs. leuprolide. Abarelix: approved 2003, withdrawn due to 3.7% anaphylaxis rate. Degarelix has superior safety data and remains in active use.
Evidence Context Favoring Abarelix
Historical pharmacology research only; abarelix has no current clinical role.
Evidence Context Favoring Degarelix
Any prostate cancer or GnRH antagonist research - degarelix is the evidence-supported choice with active FDA approval.
Side-by-Side Snapshot
| Evidence grade | Abarelix: Level A Degarelix: Level A |
|---|---|
| Research status | Abarelix: Historical FDA Approval Degarelix: FDA Approved |
| Primary category | Abarelix: Sexual Health Degarelix: Sexual Health |
| Cited studies | Abarelix: 2 Degarelix: 3 |